[QUANTITATIVE AND QUALITATIVE CHARACTERISTICS OF THE POPULATION OF PATIENTS WITH LIVER CIRRHOSIS IN MOSCOW].

Autor:	Kornilova EB; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, 115088, Moscow, Russia, ekaterinakornilova2017@gmail.com., Zavyalov AA; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, 115088, Moscow, Russia., Hołownia-Voloskova ME; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, 115088, Moscow, Russia.; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 10002, Warsaw, Poland., Ar'kova ES; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, 115088, Moscow, Russia., Tolkushin AG; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, 115088, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny [Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med] 2021 Aug; Vol. 29 (Special Issue), pp. 1287-1291.
DOI:	10.32687/0869-866X-2021-29-s2-1287-1291
Abstrakt:	Introduction: Liver cirrhosis is a major but preventable cause of health loss worldwide. The era of «big data» allows us to evaluate this nosology in a new format. Purpose: Evaluation of the registered population of patients with cirrhosis of the liver of cirrhosis of various etiology in Moscow. Moscow. Materials and Methods: Based on the data of the Moscow Department of Healthcare for the drug provision for the period from 2017 to 2019. Тhe population of patients with an established diagnosis of liver (other etiology) was characterized according to ICD-10 code K.74 (K74.0-74.6) according to the International Statistical Classification of Diseases and Related Health Problems of the 10th revision. Results: Over a 4-year period, more than 2 thousand patients with established diagnosis of liver cirrhosis received preferential drug provision in Moscow. The largest part of the population of patients with liver cirrhosis receiving preferential drug provision in Moscow is represented by the patients of age groups 40-59 years old and 60-79 years old, the groups 30-39 years old and 80-99 years old were comparable annually. There was a decrease in the number of patients with liver cirrhosis in the age groups of 30-39 and 18-19 years compared with the base year (2017) by 37% and 57%, respectively. At the same time, in pediatric patients (from the neonatal period to 17 years), there was an intensive increase in patients from 52 to 550% compared to the baseline year (2017).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu